Johnson & Johnson Expands Heart Disease Device Portfolio with $1.7B V-Wave Deal

New Brunswick, NJ, August 20, 2024 (Reuters) -- Johnson & Johnson will acquire V-Wave for up to $1.7 billion, including an immediate $600 million payment and potential additional sums based on performance milestones. This move underscores J&J's strategy to bolster its heart disease device segment and prepare for future growth challenges. The acquisition aligns with J&J's efforts to expand its portfolio ahead of anticipated competition for its major drug Stelara.

Read full article here.